European Journal of Surgical Oncology
Volume 35, Issue 2 , Pages 135-143, February 2009

Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients

  • P.-E. Colombo

      Affiliations

    • Department of Surgical Oncology, CRLC Val d'Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 467 613 114; fax: +33 467 618 501.
  • ,
  • A. Mourregot

      Affiliations

    • Department of Surgical Oncology, CRLC Val d'Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France
  • ,
  • M. Fabbro

      Affiliations

    • Department of Medical Oncology, CRLC Val d'Aurelle, Montpellier, France
  • ,
  • M. Gutowski

      Affiliations

    • Department of Surgical Oncology, CRLC Val d'Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France
  • ,
  • B. Saint-Aubert

      Affiliations

    • Department of Surgical Oncology, CRLC Val d'Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France
  • ,
  • F. Quenet

      Affiliations

    • Department of Surgical Oncology, CRLC Val d'Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France
  • ,
  • S. Gourgou

      Affiliations

    • Department of Biostatistics, CRLC Val d'Aurelle, Montpellier, France
  • ,
  • P. Rouanet

      Affiliations

    • Department of Surgical Oncology, CRLC Val d'Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France

Accepted 8 January 2008.

Abstract 

Aims

The standard treatment for advanced ovarian cancer consists of cytoreductive surgery associated with a platinum/paclitaxel-based chemotherapy. Nevertheless, there is still the question as to the extent and timing of the surgical debulking. The aim of this study was to evaluate the place of surgery in the therapeutic sequence.

Patients and methods

We reviewed data from all consecutive patients with stage IIIC and IV epithelial ovarian cancer, operated on at our institution between 1990 and 2005. Patients were divided into 2 groups, according to the position of surgery in the therapeutic sequence. Patients in group 1 received initial debulking surgery. Group 2 consisted of patients having received their first debulking after initial chemotherapy.

Results

Two hundred and three patients were identified and frequently underwent aggressive surgery, in particular, digestive surgery with bowel resections. Perioperative mortality and morbidity rates were low (2% and 14%, respectively) and there was no difference between the groups. Overall survival in group 1 for patients with complete cytoreduction (residual disease (RD)=0), optimal surgery (RD<1cm) or sub-optimal surgery (RD>1cm) was 50%, 30% and 14%, respectively. In group 2, overall survival following complete surgery was 30%, and no long-term survival was observed when surgery was not complete at the time of interval surgery. Survival was worse for patients who had received more than 4 cycles of neoadjuvant chemotherapy.

Conclusion

This study confirms the importance of surgery in the prognosis of advanced ovarian cancer. Only the patient subgroup that underwent complete initial or interval surgery was associated with a prolonged remission. Optimal surgery with a controlled morbidity can be achieved in many cases, even if bowel resection is needed, at the time of primary debulking. In the interval cytoreductive surgery subgroup, the response to initial chemotherapy and surgery was found to be essential for prognosis.

Keywords: Advanced ovarian cancer, Cytoreductive surgery, Initial surgery, Interval surgery

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0748-7983(08)00020-6

doi:10.1016/j.ejso.2008.01.005

European Journal of Surgical Oncology
Volume 35, Issue 2 , Pages 135-143, February 2009